Pay in 4 interest-free payments of $7.07 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
A once-weekly injectable glucose-dependent insulinotropic polypeptide/GLP-1 dual agonist conferred up to 14.7% weight loss at 13 weeks for adults with overweight or obesity, according to findings from the VENTURE trial published in Obesity
Richalet JP
Xie, Z., Hu, J., Gu, H., Li, M
Preliminary trials suggest a reduction in alcohol craving and relapse by modulating brain reward circuits
Silvestro is a board-certified obesity medicine physician and Associate Director of Clinical Content and Education at Ro, so you can say he knows a thing or two (or 20+) about Ros weight loss offerings
The pharmacy ships it with tracking
US$ 28.70
US$ 24.67
US$ 28.45
